Omeprazole formulations and bioavailability
Pro Research Analysisby 
Searched over 200M research papers
Omeprazole Formulations: Types and Stability
Omeprazole is a proton pump inhibitor with low water solubility and is unstable in acidic environments, which makes its formulation challenging. To address these issues, several types of oral formulations have been developed, including enteric-coated granules, capsules, suspensions, buccal adhesive tablets, and floating in situ gels. Enteric-coated formulations are designed to protect omeprazole from stomach acid, ensuring it reaches the intestine for absorption, while other approaches like co-crystals, buccal tablets, and floating gels aim to improve stability and bioavailability in different ways 5678+1 MORE.
Bioavailability of Omeprazole: Enteric-Coated vs. Plain Formulations
Studies consistently show that enteric-coated omeprazole formulations have higher bioavailability compared to plain (non-coated) formulations. Enteric coating prevents degradation in the stomach, allowing more drug to be absorbed in the intestine. For example, in horses, enteric-coated omeprazole had about double the bioavailability of plain omeprazole, and feeding status had minimal impact on absorption . Similarly, in humans, enteric-coated and commercial capsule formulations are shown to be bioequivalent, with comparable pharmacokinetic parameters such as Cmax (peak concentration), Tmax (time to peak), and AUC (area under the curve) 1234.
Comparative Bioavailability and Bioequivalence of Commercial Products
Multiple studies comparing different commercial and generic omeprazole products (such as Losec, Omelcid, and Zimor) have found that these formulations are bioequivalent. This means they provide similar levels of drug in the bloodstream, as measured by Cmax and AUC, and meet regulatory standards for bioequivalence 1234. These findings support the use of generic omeprazole products as effective alternatives to brand-name formulations.
Novel Formulations to Enhance Omeprazole Bioavailability
Recent research has focused on developing new omeprazole formulations to further improve bioavailability and stability:
- Co-crystal dry suspensions: These use particle engineering to enhance solubility and stability, resulting in significantly improved bioavailability compared to pure omeprazole .
- Buccal adhesive tablets: Designed to release omeprazole through the cheek, these tablets protect the drug from stomach acid and first-pass metabolism, achieving measurable plasma concentrations and offering an alternative route for patients who cannot swallow pills .
- Floating in situ gels: These formulations float in the stomach, prolonging gastric residence time and sustaining drug release, which helps protect omeprazole from acidic degradation and enhances bioavailability .
- Buffered suspensions: Adding sodium bicarbonate to omeprazole suspensions improves stability in acidic environments and increases drug recovery, making these formulations suitable for immediate-release and for patients with swallowing difficulties .
Factors Affecting Omeprazole Bioavailability
The bioavailability of omeprazole is influenced by several factors:
- Formulation type: Enteric-coated and buffered formulations protect omeprazole from acid degradation, leading to higher bioavailability 579.
- Dissolution rate: Slower-dissolving granules can reduce absorption, while formulations that dissolve efficiently in the intestine improve bioavailability .
- Food intake: While food can delay absorption, studies show that the timing of meals relative to dosing has minimal impact on the overall bioavailability of enteric-coated formulations 59.
- Excipients and additives: Ingredients like croscarmellose sodium in buccal tablets or sodium bicarbonate in suspensions can enhance drug release and stability 78.
Conclusion
Omeprazole’s effectiveness depends heavily on its formulation due to its instability in acidic environments. Enteric-coated capsules and granules remain the standard for optimal bioavailability, but novel approaches such as co-crystal suspensions, buccal tablets, floating gels, and buffered suspensions offer promising alternatives, especially for patients with special needs. Comparative studies confirm that many commercial and generic omeprazole products are bioequivalent, ensuring consistent therapeutic outcomes across different brands and formulations.
Sources and full results
Most relevant research papers on this topic